 | | Vol. 12.26 – 6 July, 2021 |
| |
|
|
| Incorporation of functional PZP domain of AF10 into the leukemogenic CALM-AF10 fusion prevented the transforming activity of the fusion in bone marrow-derived hematopoietic stem and progenitor cells in vitro and in vivo and abrogated CALM-AF10-mediated leukemogenesis in vivo.
[Nature Communications] |
|
|
|
 | | PUBLICATIONSRanked by the impact factor of the journal |
|
|
|
| Using scRNA-Seq analysis of chimeric mouse embryos lacking the major erythroid regulator Gata1, scientists showed that genes with the step-changes in expression dynamics during erythroid differentiation failed to be upregulated in the mutant cells, thus underscoring the coordination of modulating transcription rate along a differentiation trajectory.
[Genome Biology] |
|
|
|
| DOT1L depletion in erythroleukemic cells reduced its global occupancy without affecting the traveling ratio or the elongation rate of RNA polymerase II, suggesting that DOT1L did not play a major role in elongation in these cells.
[Proceedings of the National Academy of Sciences of the United States of America] |
|
|
|
| The authors built mouse models expressing activated Il7r (aIL7R). B-cell intrinsic aIL7R mice developed spontaneous B-cell acute lymphoblastic leukemia, demonstrating sufficiency of Il7r activating mutations in leukemogenesis.
[Leukemia] |
|
|
|
| Investigators reported the discovery of a novel class of orally bioavailable DNA methyltransferase (DNMT1)-selective inhibitors as exemplified by GSK3482364.
[Haematologica] |
|
|
|
| Researchers performed a comprehensive analysis for prognostic significance of U2AF1 mutations in an acute myeloid leukemia cohort. Functional analysis of U2AF1S34F mutation was performed in vitro.
[Cell Death & Disease] |
|
|
|
| Scientists investigated the spatial organization and transcriptional profile of individual HSCs in both wild type and Tet2−/− fetal livers, by multiplexed error robust fluorescence in situ hybridization.
[Cell Discovery] |
|
|
|
| Midostaurin resistance was overcome by a combination of midostaurin, the BCL-2 inhibitor venetoclax, and the RAC1 inhibitor Eht1864 in midostaurin-resistant acute myeloid leukemia cell lines and primary samples.
[Communications Biology] |
|
|
|
| The authors identified the RNA-binding protein RNA-binding motif protein, X-linked, and its retrogene RBMXL1 to be required for murine and human myeloid leukemogenesis.
[Nature Cancer] |
|
|
|
| | Researchers showed that GM-CSF produced by cord blood-derived inflammatory monocytes drove pre-engraftment syndrome pathology (PES) and that monocytes were the main source of IL-6 during PES. They also reported the outcome of a clinical study of tocilizumab in the treatment of steroid-refractory severe PES patients.
[Nature Communications] |
|
|
|
| Tafasitamab combined with the immunomodulatory drug lenalidomide was clinically active with a good tolerability profile in the open-label, single-arm, Phase II L-MIND study of autologous stem-cell transplant-ineligible patients with relapsed/refractory diffuse large B-cell lymphoma.
[Haematologica] |
|
|
|
| Luspatercept was a promising alternative to ESAs for a subset of transfusion-dependent patients with lower-risk myelodysplastic syndromes, namely those with a sideroblastic phenotype who were either not suitable for or had already failed erythropoietin-based treatment.
[Expert Review of Hematology] |
|
|
|
|
| Scientists review the relevance and complications of clonal hematopoiesis for the treatment of hematologic malignancies with cell therapeutic approaches.
[Leukemia] |
|
|
|
| The authors summarize the evolution of acute promyelocytic leukemia (APL) therapy, focusing on key milestones that led to the standard-of-care APL therapy available today and discuss treatment algorithms and management tips to minimize induction mortality.
[Blood Cancer Journal] |
|
|
|
|
| Syndax Pharmaceuticals, Inc. announced that the US FDA has granted Fast Track Designation to SNDX-5613 for the treatment of patients with relapsed or refractory acute leukemias harboring mixed-lineage leukemia rearranged or nucleophosmin mutation.
[Syndax Pharmaceuticals, Inc.] |
|
|
|
| Dr. Elizabeta Nemeth, professor of medicine and director of the Center for Iron Disorders at the David Geffen School of Medicine at UCLA, has been awarded the 2021 William Dameshek Prize by the American Society of Hematology for her contributions to the field of hematology.
[University of California, Los Angeles] |
|
|
|
| XNK Therapeutics AB announced that the first patient has been included in a Phase II clinical study to treat patients with multiple myeloma using XNK’s leading autologous natural killer cell-based candidate drug in combination with Sanofi’s anti-CD38 antibody Sarclisa.
[XNK Therapeutics AB] |
|
|
|
|
| November 15 – 17, 2021
Virtual |
|
|
|
|
|
| | The Technical University of Munich – Munich, Germany |
|
|
|
| | Georg-Speyer-Haus – Frankfurt, Germany |
|
|
|
| | The Westmead Institute for Medical Research – Sydney, Australia |
|
|
|
| | Heinrich Heine University Düsseldorf – Düsseldorf, Germany |
|
|
|
| | St. Jude Children’s Research Hospital – Memphis, Tennessee, United States |
|
|
|
|
Cancer Stem Cell News
Cell Therapy News
Dermal Cell News
Endothelial Cell News
ESC & iPSC News
Extracellular Matrix News
Hematopoiesis News
Hepatic Cell News
Human Immunology News
Immune Regulation News
Intestinal Cell News
Mammary Cell News
Mesenchymal Cell News
Muscle Cell News
Neural Cell News
Organoid News
Pancreatic Cell News
Prostate Cell News
Pulmonary Cell News
